Trial Profile
Efficacy of triple therapy for Helicobacter pylori infection using amoxicillin and clarithromycin and TAK-438 (vonoprazan) which is a novel potassium-competitive acid blocker to the patients treated unsuccessfully with PPI, amoxicillin and clarithromycin.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 May 2016
Price :
$35
*
At a glance
- Drugs Vonoprazan (Primary) ; Amoxicillin; Clarithromycin
- Indications Helicobacter infections
- Focus Therapeutic Use
- 18 Jun 2015 New trial record